Evidence map›Paper›PMID 33139955›Full record

ArticleNature protocols2020

Proximity labeling in mammalian cells with TurboID and split-TurboID.

Kelvin F Cho, Tess C Branon, Namrata D Udeshi, Samuel A Myers, Steven A Carr, Alice Y Ting

Abstract read
PubMed Publisher
In one paragraph

Article in Nature protocols, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 353 papers.

0numbers the graph read from it
0cells of the map it votes in
353citing papers in PubMed
18.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

353 citing papers in PubMed, 504 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article

293 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Kelvin F Cho *Cancer Biology Program, Stanford University, Stanford, CA, USA.
Tess C Branon *Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, CA, USA.
Namrata D UdeshiBroad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0001-5312-1402
Samuel A MyersBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Steven A CarrBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Alice Y TingDepartment of Genetics, Stanford University, Stanford, CA, USA. ayting@stanford.edu.ORCID http://orcid.org/0000-0002-8277-5226
Broad Institute · USChan Zuckerberg Initiative (United States) · USStanford University · USUniversity of California, Berkeley · US

Funding

Leveraging innovative technologies in basic and clinical cancer researchT32CA009302 · NCI · STANFORD UNIVERSITY · PI LAURA D ATTARDI, Aaron M Newman · 1985 to 2026
$19.1M
Mapping protein communication between organs in homeostasis and diseaseR01DK121409 · NIDDK · HARVARD MEDICAL SCHOOL · PI CARR, STEVEN A, MCMAHON, ANDREW P. · 2018 to 2022
$8.3M
NCI NIH HHS T32 CA009302NIDDK NIH HHS R01 DK121409
6 · The paper itself

Abstract

This protocol describes the use of TurboID and split-TurboID in proximity labeling applications for mapping protein-protein interactions and subcellular proteomes in live mammalian cells. TurboID is an engineered biotin ligase that uses ATP to convert biotin into biotin-AMP, a reactive intermediate that covalently labels proximal proteins. Optimized using directed evolution, TurboID has substantially higher activity than previously described biotin ligase-related proximity labeling methods, such as BioID, enabling higher temporal resolution and broader application in vivo. Split-TurboID consists of two inactive fragments of TurboID that can be reconstituted through protein-protein interactions or organelle-organelle interactions, which can facilitate greater targeting specificity than full-length enzymes alone. Proteins biotinylated by TurboID or split-TurboID are then enriched with streptavidin beads and identified by mass spectrometry. Here, we describe fusion construct design and characterization (variable timing), proteomic sample preparation (5-7 d), mass spectrometric data acquisition (2 d), and proteomic data analysis (1 week).

Indexed as

BiotinylationMass SpectrometryProtein Interaction MappingStaining and Labeling

Identifiers

PMID33139955
OpenAlexW3095688667

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.